… It is of interest that the majority of our “real life” patients with normal CrCl had plasma
dabigatran concentrations in the low range of the interval measured in the RE-LY study. Thus, the …

… In the RE-LY trial, dabigatran 150 mg twice daily was superior to … and dabigatran 110 mg
twice daily was noninferior. Both doses greatly reduced hemorrhagic stroke, and dabigatran …

… research groups to the evaluation of dabigatran clinical performance in real-life settings. …
that dabigatran is associated with generally good clinical performance in the Italian real-life …

… of the dabigatran effect may be desirable. We aimed to assess the variability of dabigatran
trough and peak concentration and explore the potential relationship between dabigatran …

… to date of real-life idarucizumab use, the antidote proved to be an important adjunct in the
management of bleeding patients taking dabigatran and allowed patients on dabigatran to …

… We report 11 real-life clinical cases in which idarucizumab was used after multidisciplinary
… requiring rapid reversal of the anticoagulant effect of dabigatran. The indication for long-term …

… of both dosages of dabigatran regarding major of fatal bleeding in a “real life” single center
… tolerated dabigatran treatment without significant side effects. The efficacy of dabigatran was …

… switching from VKA therapy to dabigatran in real life. … ‘VKA to dabigatran switching’ patients
in the dabigatran group, … at the time of initiation of dabigatran and acenocoumarol. For this, …

… warfarin or dabigatran) choice was based on the 2011 to 2012 population of warfarin and
dabigatran patients; the latter model on dabigatran dose was based on all dabigatran patients. …

… for at least 3 months with dabigatran and followed by our anticoagulant clinic. We obtained
information on the number of capsules of dabigatran dispensed by the pharmacy of each …